1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Biophytis SA

Biophytis SA

0.04
EUR
-0.01
(-12.03%)
Mar 03Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-9.44
-12.84
-1,167.86
-1,392.79
-1,348.49
-1,135.82
-1,218.83
-462.09
-286.14
-150.43
-34.05
- -
- -
Free Cash Flow per Basic Share
- -
-14.62
-11.98
-739.43
-1,206.65
-1,046.71
-988.27
-986.4
-180.31
-221.65
-118.83
-26.18
-3.21
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
26.63
-66.65
-192.64
2,038.67
798.77
1,716.58
569.28
-375.36
24.78
46.61
-8.56
-4.03
-3.59
- -
Tangible Book Value per Share
26.63
-66.65
-192.64
1,645.28
425.64
1,554.05
414.77
-484.51
-4.03
24.59
-20.66
-6.78
-4.56
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
3
13
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
Net Income, GAAP
- -
-1
-1
-5
-8
-11
-14
-19
-26
-31
-24
-17
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
-1
9
3
19
11
-6
1
9
-1
-4
-12
- -
LT Debt
- -
- -
- -
- -
- -
- -
6
4
1
5
4
3
- -
- -
Total Equity
- -
- -
-1
12
5
21
7
-8
2
6
-2
-4
-10
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-98.33
-88.54
-99
- -
- -
-766.24
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
ST Debt
7
7
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
23
Market Capitalization
- -
- -
3

Working Capital

EUR

•

in mil. unless spec.
Jun'24
Dec'24
Jun'25
Total Current Assets
6
4
- -
Cash, Cash Equivalents & STI
2
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
16
- -
Payables & Accruals
5
5
- -
ST Debt
7
7
5
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-95.62%
29.71%
149.47%
Free Cash Flow
62.18%
4.22%
-33.99%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-34.05
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Stanislas Veillet
Full Time Employees
20
Sector
Health technology
Industry
Pharmaceuticals: other
Address
14 avenue de l'Opéra Paris IF France 75001
IPO Date
Jul 13, 2015
Website
biophytis.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Biophytis S.A. Biophytis S.A. is a clinical-stage biotechnology company that develops therapeutics targeting degenerative processes associated with aging and age-related diseases, with a primary focus on enhancing biological resilience to counteract stresses such as inflammatory, oxidative, metabolic, and viral factors; its lead product candidate is BIO101 (also known as 20-hydroxyecdysone or Sarconeos), an oral small molecule in advanced development for sarcopenia through the SARA program preparing for a Phase 3 pivotal study, mobility impairment in obesity via the OBA program initiating Phase 2 trials in the U.S. and Europe, Duchenne muscular dystrophy (DMD) with a pediatric formulation (MYODA), and previously for severe respiratory failure in COVID-19 (COVA program); it also advances BIO201, an oral small molecule for retinopathies including dry age-related macular degeneration and Stargardt disease. Founded in 2006 and headquartered in Paris, France, the company operates primarily in Europe with subsidiaries in the United States and Brazil, and targets patient populations suffering from neuromuscular disorders, obesity-related mobility issues, and retinal diseases in global markets including North America, Latin America, Asia, and Europe. Recent developments include an exclusive licensing agreement with Blanver in Latin America for BIO101 worth up to €108 million signed in 2024, contracts with local agents in Japan/South Korea and China/Southeast Asia to identify partners, entry into exclusive negotiations with a Chinese pharmaceutical company for BIO101 in early 2025, a memorandum with Asian partners and formation of a Hong Kong joint venture for up to USD 20 million to support a Phase 3 sarcopenia trial, a co-development agreement with AskHelpU for amyotrophic lateral sclerosis (ALS), securing public funding in Brazil for the OBA Phase 2 trial, and an €8.6 million refinancing to strengthen its financial position.